Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1-2 Study of Safety and Efficacy of Intrathecal Trastuzumab Administration in Metastatic HER2 Positive Breast Cancer Patients Developing Carcinomatous Meningitis

Trial Profile

Phase 1-2 Study of Safety and Efficacy of Intrathecal Trastuzumab Administration in Metastatic HER2 Positive Breast Cancer Patients Developing Carcinomatous Meningitis

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab (Primary) ; Trastuzumab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; HER2 positive breast cancer; Meningeal carcinomatosis
  • Focus Adverse reactions
  • Acronyms HIT
  • Most Recent Events

    • 09 Jul 2019 Status changed from active, no longer recruiting to completed.
    • 07 Apr 2018 Results (n=19) of phase1 part of study assessing tolerability and efficacy of intrathecal trastuzumab administration for the treatment of patients with metastatic HER2-positive breast cancer, developing carcinomatous meningitis, were published in the European Journal of Cancer.
    • 02 Nov 2017 Planned primary completion date changed from 1 Sep 2017 to 1 May 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top